{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:09:27Z","timestamp":1791320967387,"version":"4.3.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.semnephrol.2018.12.002","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T03:05:31Z","timestamp":1551323131000},"page":"120-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Kidney Safety Assessment: Current Practices in Drug Development"],"prefix":"10.1016","volume":"39","author":[{"given":"Sean P.","family":"Troth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Simutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank D.","family":"Sistare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.12.002_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0002","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.copbio.2005.10.014","article-title":"Innovation and greater probability of success in drug discovery and development \u2013 from target to biomarkers","volume":"16","author":"Kola","year":"2005","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3109\/15563650.2011.615319","article-title":"Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury","volume":"49","author":"Waring","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0004","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yrtph.2008.04.006","article-title":"Safety evaluation to support First-In-Man investigations II: toxicology studies","volume":"51","author":"Baldrick","year":"2008","journal-title":"Regul Toxicol Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.semnephrol.2018.12.002_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0168-8278(97)80494-1","article-title":"Hepatotoxicity in drug development: detection, significance and solutions","volume":"26","author":"Ballet","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0006","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.yrtph.2014.07.008","article-title":"Target organ profiles in toxicity studies supporting human dosing: an assessment of recovery and chronic dosing","volume":"70","author":"Horner","year":"2014","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0007","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0378-4274(81)90125-9","article-title":"Target organ toxicity","volume":"8","author":"Heywood","year":"1981","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0008","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrd1329","article-title":"First dose of potential new medicines to humans: how animals help","volume":"3","author":"Greaves","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0009","first-page":"141","article-title":"An integrated strategy for leveraging novel tissue transcriptional biomarkers, translational safety biomarkers, and advanced in vitro models to reduce drug attrition and improve pharmaceutical safety in drug discovery and development","volume":"162","author":"Sistare","year":"2018","journal-title":"Toxicologist Suppl Toxicol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10544-016-0102-y","article-title":"Hollow fiber integrated microfluidic platforms for in vitro co-culture of multiple cell types","volume":"18","author":"Huang","year":"2016","journal-title":"Biomed Microdevices"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/toxsci\/kfr112","article-title":"Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat","volume":"122","author":"Harpur","year":"2011","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0013","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0192623312464306","article-title":"Correlation of histopathology, urinary biomarkers, and gene expression responses following hexachloro-1:3-butadiene-induced acute nephrotoxicity in male Hanover Wistar rats: a 28-day time course study","volume":"41","author":"Maguire","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/cc10251","article-title":"Diagnosis of kidney damage using novel acute kidney injury biomarkers: assessment of kidney function alone is insufficient","volume":"15","author":"Murray","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0016","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ki.2013.374","article-title":"Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference","volume":"85","author":"Murray","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0017","unstructured":"Review submission of the qualification of seven biomarkers of drug-induced nephrotoxicity in rats. 2008. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/UCM285031.pdf. Accessed January 4, 2019."},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0020","series-title":"Boorman's pathology of the rat: reference and atlas","first-page":"125","article-title":"Kidney","author":"Seely","year":"2018"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0021","series-title":"The clinical chemistry of laboratory animals","first-page":"407","article-title":"Evaluation of renal function and injury","author":"Bounous","year":"2017"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0024","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0025","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.japh.2017.05.014","article-title":"The growing role of biologics and biosimilars in the United States: perspectives from the APhA Biologics and Biosimilars Stakeholder Conference","volume":"57","author":"Crespi-Lofton","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/1523-1747.ep12543582","article-title":"Physicochemical and functional relationships of immune complexes","volume":"74","author":"Mannik","year":"1980","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0027","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0192623314526475","article-title":"Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies","volume":"42","author":"Rojko","year":"2014","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0029","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/0192623318789399","article-title":"Drug-induced glomerulonephritis: the spectre of biotherapeutic and antisense oligonucleotide immune activation in the kidney","volume":"46","author":"Frazier","year":"2018","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0030","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0192623317710014","article-title":"Regulatory forum opinion piece*: imaging applications in toxicologic pathology-recommendations for use in regulated nonclinical toxicity studies","volume":"45","author":"Maronpot","year":"2017","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13361-015-1254-3","article-title":"Mass spectrometry imaging of drug related crystal-like structures in formalin-fixed frozen and paraffin-embedded rabbit kidney tissue sections","volume":"27","author":"Bruinen","year":"2016","journal-title":"J Am Soc Mass Spectrom"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00795-017-0157-8","article-title":"Quantified kidney echogenicity in mice with renal ischemia reperfusion injury: evaluation as a noninvasive biomarker of acute kidney injury","volume":"50","author":"Murata","year":"2017","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0033","first-page":"60","article-title":"Monitoring kidney safety in drug development: emerging technologies and their implications","volume":"11","author":"Dieterle","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0034","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1109\/TUFFC.2005.1417273","article-title":"High-frequency, nonlinear flow imaging of microbubble contrast agents","volume":"52","author":"Goertz","year":"2005","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/taap.2000.9055","article-title":"The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats","volume":"169","author":"Mutlib","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0036","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/jama.1993.03510160055029","article-title":"Examining product risk in context. Market withdrawal of zomepirac as a case study","volume":"270","author":"Ross-Degnan","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0037","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.dmpk.2016.11.002","article-title":"Toxicological potential of acyl glucuronides and its assessment","volume":"32","author":"Iwamura","year":"2017","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0038","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/toxsci\/kfs238","article-title":"A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models","volume":"130","author":"Harrill","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0039","first-page":"64","article-title":"Universal toxicity gene signatures for early identification of drug-induced tissue injuries in rats","volume":"162","author":"Glaab","year":"2018","journal-title":"Toxicologist Suppl Toxicol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/toxsci\/kfr339","article-title":"Evaluation of drugs with specific organ toxicities in organ-specific cell lines","volume":"126","author":"Lin","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0041","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138620710790596736","article-title":"Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance","volume":"13","author":"McKim","year":"2010","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0042","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jcp.24683","article-title":"3D cell culture systems: advantages and applications","volume":"230","author":"Ravi","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-10-26","article-title":"3D collagen type I matrix inhibits the antimigratory effect of doxorubicin","volume":"10","author":"Millerot-Serrurot","year":"2010","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0044","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1016\/j.biomaterials.2010.07.064","article-title":"Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells","volume":"31","author":"Loessner","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/01926230490508821","article-title":"Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology","volume":"32","author":"Vickers","year":"2004","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0046","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/00498254.2012.725142","article-title":"Use of precision-cut renal cortical slices in nephrotoxicity studies","volume":"43","author":"Baverel","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0047","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1517\/17425255.2014.967681","article-title":"Cell- and biomarker-based assays for predicting nephrotoxicity","volume":"10","author":"Huang","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0048","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.kint.2016.06.011","article-title":"Development of a microphysiological model of human kidney proximal tubule function","volume":"90","author":"Weber","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0049","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-017-0069","article-title":"Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip","volume":"1","author":"Musah","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/1389200219666180309101844","article-title":"Kidney-on-a-chip: a new technology for predicting drug efficacy, interactions, and drug-induced nephrotoxicity","volume":"19","author":"Lee","year":"2018","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0051","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1039\/C5LC00392J","article-title":"A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents","volume":"15","author":"Maschmeyer","year":"2015","journal-title":"Lab Chip"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0052","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tibtech.2015.11.001","article-title":"Kidney-on-a-chip technology for drug-induced nephrotoxicity screening","volume":"34","author":"Wilmer","year":"2016","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0053","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature15695","article-title":"Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis","volume":"526","author":"Takasato","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0054","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nbt.3392","article-title":"Nephron organoids derived from human pluripotent stem cells model kidney development and injury","volume":"33","author":"Morizane","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0055","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ncb3312","article-title":"Organoids as an in vitro model of human development and disease","volume":"18","author":"Fatehullah","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0056","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/0960327115605440","article-title":"Computational toxicology: its essential role in reducing drug attrition","volume":"34","author":"Naven","year":"2015","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0057","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13065-015-0139-7","article-title":"Identification of structural alerts for liver and kidney toxicity using repeated dose toxicity data","volume":"9","author":"Pizzo","year":"2015","journal-title":"Chem Cent J"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0058","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.yrtph.2009.01.007","article-title":"Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities","volume":"54","author":"Matthews","year":"2009","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.002_bib0059","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1021\/tx400249t","article-title":"Human nephrotoxicity prediction models for three types of kidney injury based on data sets of pharmacological compounds and their metabolites","volume":"26","author":"Lee","year":"2013","journal-title":"Chem Res Toxicol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:33:05Z","timestamp":1759447985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518301815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0270929518301815"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.12.002","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Safety Assessment: Current Practices in Drug Development","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}